Abstract: The present invention involves a compartmentalized microfluidic device using one or more separators. Each separator has a plurality of microfluidic channels and the separators are oriented in a perpendicular direction to the substrate. The vertical integration of the microfluidic components enables realization of 3D device features with high aspect ratio.

Abstract: A method for processing a virtual digital human includes: obtaining a key point image sequence of a reference role; determining key point data of the virtual digital human corresponding to key point data in the key point image sequence based on the key point data in the key point image sequence when the virtual digital human is projected into a two-dimensional space; obtaining a bone rotation coefficient sequence of the virtual digital human based on the key point data of the virtual digital human; and driving the virtual digital human to perform corresponding actions based on the bone rotation coefficient sequence.

Abstract: A method for generating an object model includes: obtaining an initial morphable model; obtaining a plurality of initial images of an object, and depth images corresponding to the plurality of initial images; obtaining a plurality of target topological images by processing the plurality of initial images based on the depth images; obtaining a plurality of models to be synthesized by processing the initial morphable model based on the plurality of target topological images; and generating a target object model based on the plurality of models to be synthesized.

Abstract: A video sequence layout method, electronic device and storage medium are provided, and relate to fields of deep learning, virtual reality, cloud computing, video layout processing and the like. The method includes: acquiring a first video sequence, the first video sequence including a main sequence for describing a first posture of a human body and a subordinate sequence for describing a plurality of second postures of the human body; extracting the main sequence and the subordinate sequence from the first video sequence; and in a case that it is detected that a sequencing identification frame exists in the first video sequence, performing random mixed sequencing processing on video frames in the main sequence and the subordinate sequence based on the sequencing identification frame and taking a sequence combination obtained by the random mixed sequencing processing as a second video sequence.

Abstract: A video sequence layout method, electronic device and storage medium are provided, and relate to fields of deep learning, virtual reality, cloud computing, video layout processing and the like. The method includes: acquiring a first video sequence, the first video sequence including a main sequence for describing a first posture of a human body and a subordinate sequence for describing a plurality of second postures of the human body; extracting the main sequence and the subordinate sequence from the first video sequence; and in a case that it is detected that a sequencing identification frame exists in the first video sequence, performing random mixed sequencing processing on video frames in the main sequence and the subordinate sequence based on the sequencing identification frame and taking a sequence combination obtained by the random mixed sequencing processing as a second video sequence.

Abstract: Methods for producing new neurons in the brain in vivo are provided according to aspects of the present invention which include introducing NeuroD1 into a glial cell, particularly into a reactive astrocyte or NG2 cell, thereby “converting” the reactive glial cell to a neuron. Methods of producing a neuronal phenotype in a glial cell are provided according to aspects of the present invention which include expressing exogenous NeuroD1 in the glial cell, wherein expressing exogenous NeuroD1 includes delivering an expression vector, such as a viral expression vector, including a nucleic acid encoding the exogenous NeuroD1 to the glial cell.

Abstract: Methods for producing new neurons in the brain in vivo are provided according to aspects of the present invention which include introducing NeuroD1 into a glial cell, particularly into a reactive astrocyte or NG2 cell, thereby “converting” the reactive glial cell to a neuron. Methods of producing a neuronal phenotype in a glial cell are provided according to aspects of the present invention which include expressing exogenous NeuroD1 in the glial cell, wherein expressing exogenous NeuroD1 includes delivering an expression vector, such as a viral expression vector, including a nucleic acid encoding the exogenous NeuroD1 to the glial cell.

Abstract: This document provides methods and materials for generating GABAergic neurons in brains. For example, methods and materials for using nucleic acid encoding a NeuroD1 polypeptide and nucleic acid encoding a Dlx2 polypeptide to trigger glial cells (e.g., NG2 glial cells or astrocytes) within the brain (e.g., striatum) into forming GABAergic neurons (e.g., neurons resembling medium spiny neurons such as DARPP32-positive GABAergic neurons) that are functionally integrated into the brain of a living mammal (e.g., a human) are provided.

Abstract: This document provides methods and materials for generating GABAergic neurons in brains. For example, methods and materials for using nucleic acid encoding a NeuroD1 polypeptide and nucleic acid encoding a Dlx2 polypeptide to trigger glial cells (e.g., NG2 glial cells or astrocytes) within the brain (e.g., striatum) into forming GABAergic neurons (e.g., neurons resembling medium spiny neurons such as DARPP32-positive GABAergic neurons) that are functionally integrated into the brain of a living mammal (e.g., a human) are provided.

Abstract: This document provides methods and materials for treating brain injuries. For example, methods and materials for using nucleic acid encoding a NeuroD1 polypeptide to convert reactive astrocytes within a brain (e.g., cerebral cortex) into functional neurons (e.g., neurons that can be functionally integrated into the brain of a living mammal (e.g., a human)) are provided.

Abstract: This document provides methods and materials for treating a mammal having Huntington's disease. For example, methods and materials for forming GABAergic neurons that are functionally integrated into the brain of a living mammal (e.g., a human) and/or for modifying one or both huntingtin (Htt) genes (or HTT RNAs or HTT polypeptides) present in a mammal with Huntington's disease are provided.

Abstract: This document relates to methods and materials for reducing memory loss. For example, methods and materials for using inhibitors of GAT-3 polypeptide activity to reduce memory loss in mammals suffering from Alzheimer's disease are provided.

Abstract: Methods for producing new neurons in the brain in vivo are provided according to aspects of the present invention which include introducing NeuroD1 into a glial cell, particularly into a reactive astrocyte or NG2 cell, thereby “converting” the reactive glial cell to a neuron. Methods of producing a neuronal phenotype in a glial cell are provided according to aspects of the present invention which include expressing exogenous NeuroD1 in the glial cell, wherein expressing exogenous NeuroD1 includes delivering an expression vector, such as a viral expression vector, including a nucleic acid encoding the exogenous NeuroD1 to the glial cell.

Abstract: Methods for producing new neurons in the brain in vivo are provided according to aspects of the present invention which include introducing NeuroD1 into a glial cell, particularly into a reactive astrocyte or NG2 cell, thereby “converting” the reactive glial cell to a neuron. Methods of producing a neuronal phenotype in a glial cell are provided according to aspects of the present invention which include expressing exogenous NeuroD1 in the glial cell, wherein expressing exogenous NeuroD1 includes delivering an expression vector, such as a viral expression vector, including a nucleic acid encoding the exogenous NeuroD1 to the glial cell.

Abstract: Methods for producing new neurons in the brain in vivo are provided according to aspects of the present invention which include introducing NeuroD1 into a glial cell, particularly into a reactive astrocyte or NG2 cell, thereby “converting” the reactive glial cell to a neuron. Methods of producing a neuronal phenotype in a glial cell are provided according to aspects of the present invention which include expressing exogenous NeuroD1 in the glial cell, wherein expressing exogenous NeuroD1 includes delivering an expression vector, such as a viral expression vector, including a nucleic acid encoding the exogenous NeuroD1 to the glial cell.

Abstract: This document relates to methods and materials for reducing memory loss. For example, methods and materials for using inhibitors of GAT-3 polypeptide activity to reduce memory loss in mammals suffering from Alzheimer's disease are provided.

Abstract: The disclosure relates to methods and compositions for reducing memory loss. Specifically, methods of using inhibitors of GAT-3 polypeptide activity to reduce memory loss in mammals suffering from Alzheimer's disease (AD) are provided. Further provided are methods for identifying a mammal as having AD by detecting the presence of an elevated level of gamma-aminobutyric acid (GABA) within a mammal's brain.

Abstract: Methods for producing new neurons in the brain in vivo are provided according to aspects of the present invention which include introducing NeuroD1 into a glial cell, particularly into a reactive astrocyte or NG2 cell, thereby “converting” the reactive glial cell to a neuron. Methods of producing a neuronal phenotype in a glial cell are provided according to aspects of the present invention which include expressing exogenous NeuroD1 in the glial cell, wherein expressing exogenous NeuroD1 includes delivering an expression vector, such as a viral expression vector, including a nucleic acid encoding the exogenous NeuroD1 to the glial cell.

Abstract: This document provides methods and materials for generating GABAergic neurons in brains. For example, methods and materials for using nucleic acid encoding a NeuroD1 polypeptide and nucleic acid encoding a Dlx2 polypeptide to trigger glial cells (e.g., NG2 glial cells or astrocytes) within the brain (e.g., striatum) into forming GABAergic neurons (e.g., neurons resembling medium spiny neurons such as DARPP32-positive GABAergic neurons) that are functionally integrated into the brain of a living mammal (e.g., a human) are provided.

Abstract: Methods for producing new neurons in the brain in vivo are provided according to aspects of the present invention which include introducing NeuroD1 into a glial cell, particularly into a reactive astrocyte or NG2 cell, thereby “converting” the reactive glial cell to a neuron. Methods of producing a neuronal phenotype in a glial cell are provided according to aspects of the present invention which include expressing exogenous NeuroD1 in the glial cell, wherein expressing exogenous NeuroD1 includes delivering an expression vector, such as a viral expression vector, including a nucleic acid encoding the exogenous NeuroD1 to the glial cell.